[Form 4] Ainos, Inc. Warrants Insider Trading Activity

Rhea-AI Filing Summary

Schedule 13G filing – Blueprint Medicines Corp. (BPMC)

Hedge-fund complex Davidson Kempner and affiliates (M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP and managing member Anthony A. Yoseloff) disclose beneficial ownership of 0 shares and 0% of BPMC common stock as of the 14 Jul 2025 reportable event. Rows 5-8 of each cover page show no sole or shared voting or dispositive power. Item 5 confirms they now hold “5 percent or less” of the class. Historically, the group previously exceeded the 5 % threshold, triggering the original 13G; this amendment reflects a complete exit or reduction below the reporting threshold.

All reporting persons list the same business address (9 W 57th St., New York) and certify the shares were not acquired to influence control. The filing therefore signals that a significant institutional holder has fully unwound its position in Blueprint Medicines.

Insights

Portfolio Manager

TL;DR: Davidson Kempner reports 0% stake in BPMC, indicating full exit by a once-large holder.

The filing shows all affiliated entities now control no shares. Hedge-fund departures can signal profit-taking or diminished conviction. While not dilutive, it removes a potential “sticky” shareholder that might have supported the stock during volatility. Absence of voting power also reduces activist risk from this group. Investors should monitor trading volumes around 14 Jul 2025 to gauge if the exit pressured share price.

Corporate Governance Specialist

TL;DR: Governance impact minimal; disclosure formalises sub-5 % status.

Because the group certifies no intent to influence control, governance ramifications are limited. The exit diminishes concentration among top holders, potentially broadening the float. Management loses a knowledgeable biotech investor but gains marginally more flexibility in strategic actions without needing to consult this fund.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Taiwan Carbon Nano Technology Corp

(Last) (First) (Middle)

10F-2, NO. 66, SHENGYI 5TH RD.,

(Street)

ZHUBEI CITY F5 302

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ainos, Inc. [ AIMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/17/2025		S		7,001(1)	A	$2.8033	1,087,103	D
Common Stock	07/18/2025		S		7,000(1)	A	$2.8067	1,080,103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person sold shares of common stock to cover income tax obligations.

	Taiwan Carbon Nano Technology Corporation By: /s/ Chun-Hsien Tsai, Chairman, Chief Executive Officer	07/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did Davidson Kempner file a Schedule 13G for Blueprint Medicines (BPMC)?

Because its aggregate holdings dropped to 5 % or less, requiring an update under SEC Rule 13d-1.

How many Blueprint Medicines shares does Davidson Kempner currently own?

The filing lists 0 shares with no voting or dispositive power.

What percentage of BPMC’s outstanding shares does this represent?

The reported ownership is 0 % of the common stock class.

Does the filing indicate an attempt to influence Blueprint Medicines’ control?

No. The certification states the securities were not acquired to change or influence control.

When was the reportable event triggering this filing?

The event date is 14 July 2025, with signatures dated 21 July 2025.